FDA Brief

Warning letters Drugs

FDA warning letter to

Par Health USA, LLC & Endo USA, Inc.

High riskIssued Apr 15Posted Apr 21Center for Drug Evaluation and Research (CDER)

FDA cited Par Health USA/Endo USA’s Rochester plant for sterile injectable contamination-control, media fill, and visual inspection failures after an October 2025 inspection.

What happened

FDA inspected the ENDO USA drug manufacturing facility at 870 Parkdale Road, Rochester, from October 6 to 20, 2025. The investigators found significant CGMP (current good manufacturing practice) violations for sterile injectables: aseptic processing lines lacked adequate barrier protection and required excessive manual interventions, environmental monitoring and airflow studies were inadequate, media fills did not simulate worst-case conditions, and visual inspection could not reliably detect particulates. FDA reviewed the company’s November 10, 2025 response and found it inadequate.

What FDA found

  1. Aseptic processing areas and lines were not designed or controlled to prevent contamination; several lines called restricted access barrier systems lacked basic design features and required hundreds of high-risk manual interventions.

    21 CFR 211.42(c)(10)
  2. Environmental monitoring did not periodically assess all critical filling equipment, and dynamic airflow studies showed air patterns failed to protect exposed sterile product and product-contact equipment.

    21 CFR 211.42(c)(10)
  3. Media fills did not accurately simulate routine production because they used far fewer worst-case interventions and much smaller unit counts than commercial batches, and operators showed poor aseptic technique.

    21 CFR 211.113(b)
  4. The visual inspection program was inadequate: personnel often could not detect critical 150-micron or larger particulates at 70% probability, some critical defects were classified as major, and procedures allowed multiple re-inspections.

    21 CFR 211.160(b)
  5. The quality system was ineffective, and the quality unit was not enabled to exercise proper authority or sufficiently oversee production.

What FDA wants

FDA asks the company to respond in writing within 15 working days describing what it has done to correct the violations and prevent recurrence, and to provide independent risk assessments and remediation plans for aseptic processing, media fills, visual inspection, investigations, and supplier qualification. If corrections cannot be completed in that time, the company must explain the delay and give a completion schedule.

Who should pay attention

  • hospitals and patients using sterile injectables made at this site
  • brands or distributors that buy finished sterile products from this contract manufacturer
  • companies that rely on Endo USA or Par Health USA as a supplier of injectable drugs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  2. Baxter International Inc.

    Baxter's Round Lake injectable drug plant violated CGMP (manufacturing quality rules), with cephalosporin cross-contamination and sterile processing failures.

    High risk
  3. Fresenius Kabi USA LLC

    FDA warns Fresenius Kabi USA over manufacturing failures for sterile injectables at Melrose Park, including endotoxin contamination and media fill failures.

    High risk
  4. Jabil Inc.

    FDA warned Jabil Inc. after an inspection found inadequate investigations of mold and sterility failures at its sterile injectable contract manufacturer.

    High risk